SCHEMBL3316973

SCHEMBL3316973

Clc1cccc(CN2CCC(Sc3cc4ccncc4cc3Br)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 6/20 0.48
ROCK1 Q13464 4/20 0.48
CCR2 P41597 1/20 0.48
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
GAA P10253 2/20 0.44
HTT P42858 2/20 0.44
GLA P06280 1/20 0.44
MAPT P10636 1/20 0.44
ATM Q13315 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
SIGMAR1 Q99720 1/20 0.43
HDAC8 Q9BY41 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ACHE P22303 1/20 0.40
BACE1 P56817 1/20 0.40
DRD4 P21917 3/20 0.40
DRD2 P14416 2/20 0.40
DRD3 P35462 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3319720 0.91 ROCK2 (0.38) ROCK2ROCK1CCR2L3MBTL1
SCHEMBL3311613 0.91 ROCK2 (0.46) ROCK2ROCK1MAPTSIGMAR1SMN1; SMN2
SCHEMBL13398888 0.90 ROCK2 (0.50) ROCK2ROCK1CCR2KDM4EALDH1A1
SCHEMBL3311507 0.90 ROCK2 (0.42) ROCK2ROCK1CCR2ALDH1A1ACHE
SCHEMBL3316802 0.87 ACHE (0.49) ROCK2ROCK1SIGMAR1HDAC8ACHE
SCHEMBL3313317 0.84 ROCK2 (0.53) ROCK2ROCK1CCR2KDM4EALDH1A1
SCHEMBL3314149 0.84 CYP2A13 (0.40) KDM4EALDH1A1SIGMAR1ACHEBACE1
SCHEMBL3313089 0.83 ROCK2 (0.46) ROCK2ROCK1CCR2ALDH1A1ATM
SCHEMBL3315940 0.82 CYP3A4 (0.47) ROCK2KDM4EALDH1A1MAPTACHE
SCHEMBL13398907 0.81 ROCK2 (0.47) ROCK2ROCK1CCR2SIGMAR1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
EP-2114920-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES Sanofi-Aventis (FR) 2009-11-11 EP disclosed
WO-2008077552-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives MYLK2, MYLK, MYLK3 ROCK2 6/4885ROCK1 5/4885CCR2 3379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.